The influence of hepatic steatosis (HS) on chronic hepatitis B (CHB) is unclear. We evaluated the influence of the degree of HS, assessed using the controlled attenuation parameter (CAP) of transient elastography (TE), on treatment outcomes in CHB patients initiated on antiviral therapy. A total of 334 patients who were initiated on entecavir or tenofovir between 2007 and 2016 with available TE results were recruited. Of the total study population, 146 (43.7%) patients had HS (CAP > 238 dB/m). Three-hundred-three patients (90.7%) achieved complete virological response (CVR) (hepatitis B virus DNA<12 IU/L), and 25 patients (7.5%) developed hepatocellular carcinoma (HCC). Among hepatitis B e antigen (HBeAg)-positive patients (n=172, 51.5%), 37 (21.5%) experienced HBeAg loss. On univariate analysis, CAP value was not associated with the probability of HCC development (P=0.380). However, lower CAP value was independently associated with higher probability of HBeAg loss among HBeAg-positive patients (hazard ratio [HR]=0.991, P=0.026) and with CVR achievement in the entire study population (HR=0.996, P=0.004). The cumulative incidence of HBeAg loss among HBeAg-positive patients was significantly higher in patients without HS than in those with HS (log-rank, P=0.022). CAP values were not correlated with HCC development in patients initiated on entecavir and tenofovir. However, CAP values were negatively correlated with the probability of HBeAg loss among HBeAg-positive patients and with CVR achievement.
30 May 2017 in Journal of Gastroenterology and Hepatology
Min Je Sung, Tae Seop Lim, Mi Young Jeon, Hye Won Lee, Beom Kyung Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jun Yong Park, and Seung Up Kim. Gut and Liver 2020;14:626-35. https://doi.org/10.5009/gnl19126
Background & Aims: Several risk prediction models for hepatocellular carcinoma (HCC) development are available. We explored whether the use of risk prediction models can dynamically predict HCC development at different time points in chronic hepatitis B (CHB) patients.Methods: Between 2006 and 2014, 1397 CHB patients were recruited. All patients underwent serial transient elastography at intervals of >6 months.Results: The median age of this study population (931 males and 466 females) was 49.0 years. The median CU‐HCC, REACH‐B, LSM‐HCC and mREACH‐B score at enrolment were 4.0, 9.0, 10.0 and 8.0 respectively. During the follow‐up period (median, 68.0 months), 87 (6.2%) patients developed HCC. All risk prediction models were successful in predicting HCC development at both the first liver stiffness (LS) measurement (hazard ratio [HR] = 1.067‐1.467 in the subgroup without antiviral therapy [AVT] and 1.096‐1.458 in the subgroup with AVT) and second LS measurement (HR = 1.125‐1.448 in the subgroup without AVT and 1.087‐1.249 in the subgroup with AVT). In contrast, neither the absolute nor percentage change in the scores from the risk prediction models predicted HCC development (all P >.05). The mREACH‐B score performed similarly or significantly better than did the other scores (AUROCs at 5 years, 0.694‐0.862 vs 0.537‐0.875).Conclusions: Dynamic prediction of HCC development at different time points was achieved using four risk prediction models, but not using the changes in the absolute and percentage values between two time points. The mREACH‐B score was the most appropriate prediction model of HCC development among four prediction models.